Frequency / statistic
kidney and urinary tract
1 supporting source
confidence 97%
novelty 60%
One French study systematically evaluated the use of SU or repaglinide after the genetic diagnosis at a median [IQR] dur
A source reports “29 of 51” in the context of diabetes metabolic: “One French study systematically evaluated the use of SU or repaglinide after the genetic diagnosis at a median [IQR] duration of 0.75 [0-5.25] years and reported that 29 of 51 (57%) patients displayed an HbA1c decrease.”
How this was derived
Numbers are quoted verbatim from the source; check the source before quoting onward.
Generated 2026-11-13, last changed
yesterday. Dedup key freq:29 of 51.
The engine re-checks this insight on every analysis run; if more sources agree, its corroboration and confidence go up and it reappears as “new”.
Evidence (1 quote)
Precision treatment of beta-cell monogenic diabetes: a systematic review
peer_reviewed
· published 2024-01-01
· live page
One French study systematically evaluated the use of SU or repaglinide after the genetic diagnosis at a median [IQR] duration of 0.75 [0-5.25] years and reported that 29 of 51 (57%) patients displayed an HbA1c decrease.
Supporting documents (1)
| Article | Source | Published | Seen | Relevance |
|---|---|---|---|---|
| Precision treatment of beta-cell monogenic diabetes: a systematic review | pmc | 2024-01-01 | yesterday | 1.00 |